If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsyGW’s.
Read More![CURE Pharmaceutical [OTCQB:CURR] Secures Patent on High Loading of Active Ingredient in Oral Thin Films](https://www.investinweed.com/wp-content/uploads/Cure-Pharmaceutical-627x376.png)
The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using its proprietary drug delivery system, CUREfilm™.
Read More
Dr. Makriyannis will champion the Company’s pursuit of biosynthesizing cannabinoids identical to those found in nature.
Read More
The company announced the completion of an interim statistical assessment of its Phase 2 trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus.
Read More
AD is one of the most common chronic inflammatory diseases with prevalence rates of up to 5% in adults and approximately 25% in children.
Read More
Get stock alerts, news & related alerts straight to your inbox!